The human gut microbiome in critical illness: disruptions, consequences, and therapeutic frontiers - PubMed (original) (raw)
Review
The human gut microbiome in critical illness: disruptions, consequences, and therapeutic frontiers
Jaeyun Sung et al. J Crit Care. 2024 Feb.
Abstract
With approximately 39 trillion cells and over 20 million genes, the human gut microbiome plays an integral role in both health and disease. Modern living has brought a widespread use of processed food and beverages, antimicrobial and immunomodulatory drugs, and invasive procedures, all of which profoundly disrupt the delicate homeostasis between the host and its microbiome. Of particular interest is the human gut microbiome, which is progressively being recognized as an important contributing factor in many aspects of critical illness, from predisposition to recovery. Herein, we describe the current understanding of the adverse impacts of standard intensive care interventions on the human gut microbiome and delve into how these microbial alterations can influence patient outcomes. Additionally, we explore the potential association between the gut microbiome and post-intensive care syndrome, shedding light on a previously underappreciated avenue that may enhance patient recuperation following critical illness. There is an impending need for future epidemiological studies to encompass detailed phenotypic analyses of gut microbiome perturbations. Interventions aimed at restoring the gut microbiome represent a promising therapeutic frontier in the quest to prevent and treat critical illnesses.
Keywords: Critical illness; Dysbiosis; Fermented foods; Gut; Microbiome.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Financial disclosures and conflicts of interest for each of the authors: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Fig. 1.
The vital role of the gut microbiome in maintaining health. The gut microbiome plays a crucial role in normal physiological processes, including regulating metabolism, supporting immunity, and fermenting non-digestible fibers to produce SCFAs. It also protects against pathogens, synthesizes vitamins, aids wound healing, and preserves intestinal homeostasis. Alterations in its composition can influence the functions of remote organs such as the brain, lungs, and liver.
Fig. 2.
Common therapeutic interventions in critical care medicine that promote gut microbiome dysbiosis. These standard medical practices can substantially reduce gut microbial diversity, predispose ICU patients to infections like C. difficile, select for antibiotic-resistant strains, and potentially result in complications such as muscle loss and an elevated risk of sepsis. This highlights the need for a balanced approach to patient care to prevent inadvertently compromising the gut health of the patient.
Fig. 3.
Alterations in the gut microbiome can significantly influence both the progression of disease and the trajectory of recovery in critically ill patients. Those with critical illnesses often exhibit diminished gut microbiome compositions in the ICU, a result of both the underlying disease and the treatments administered. Notably, these microbiome shifts can affect distant organ systems via the gut-brain, gut-lung, and gut-liver axes. Therapeutic interventions designed with the gut microbiome in mind, such as the inclusion of fermented foods, might offer promise in restoring gut health and aiding recovery from critical illnesses and post-intensive care syndrome.
Similar articles
- Pathogenesis and therapeutic opportunities of gut microbiome dysbiosis in critical illness.
Cho NA, Strayer K, Dobson B, McDonald B. Cho NA, et al. Gut Microbes. 2024 Jan-Dec;16(1):2351478. doi: 10.1080/19490976.2024.2351478. Epub 2024 May 23. Gut Microbes. 2024. PMID: 38780485 Free PMC article. Review. - Gut microbiota and host defense in critical illness.
Jacobs MC, Haak BW, Hugenholtz F, Wiersinga WJ. Jacobs MC, et al. Curr Opin Crit Care. 2017 Aug;23(4):257-263. doi: 10.1097/MCC.0000000000000424. Curr Opin Crit Care. 2017. PMID: 28548992 Review. - Letter to the editor: "The human gut microbiome in critical illness: Disruptions, consequences, and therapeutic frontiers".
Evans T, Litton E. Evans T, et al. J Crit Care. 2024 Aug;82:154768. doi: 10.1016/j.jcrc.2024.154768. Epub 2024 Mar 8. J Crit Care. 2024. PMID: 38460296 No abstract available. - Microbiome in Critical Care: An Unconventional and Unknown Ally.
Zanza C, Romenskaya T, Thangathurai D, Ojetti V, Saviano A, Abenavoli L, Robba C, Cammarota G, Franceschi F, Piccioni A, Longhitano Y. Zanza C, et al. Curr Med Chem. 2022;29(18):3179-3188. doi: 10.2174/0929867328666210915115056. Curr Med Chem. 2022. PMID: 34525908 Review. - Skin dysbiosis and loss of microbiome site specificity in critically ill patients.
Klassert TE, Zubiria-Barrera C, Denkel L, Neubert R, Schneegans A, Kulle A, Vester A, Bloos F, Schulze C, Epstude J, Gastmeier P, Geffers C, Slevogt H. Klassert TE, et al. Microbiol Spectr. 2024 Mar 5;12(3):e0307823. doi: 10.1128/spectrum.03078-23. Epub 2024 Feb 14. Microbiol Spectr. 2024. PMID: 38353551 Free PMC article.
Cited by
- Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?
Hossain SM, Ly K, Sung YJ, Braithwaite A, Li K. Hossain SM, et al. Int J Mol Sci. 2024 Sep 20;25(18):10120. doi: 10.3390/ijms251810120. Int J Mol Sci. 2024. PMID: 39337605 Free PMC article. Review. - Further gut microbiota and critical illness issues.
Pruc M, Kurek K, Swieczkowski D, Szarpak L. Pruc M, et al. Intensive Care Med. 2024 Nov;50(11):1957-1958. doi: 10.1007/s00134-024-07580-8. Epub 2024 Aug 14. Intensive Care Med. 2024. PMID: 39141087 No abstract available.
References
- Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016;164(3):337–40. - PubMed